Shanghai-headquartered Full-Life Technologies Ltd has announced a significant land acquisition deal in the Wallonie region of Belgium, with the aim of establishing a Good Manufacturing Practice (GMP)-compliant advanced radiopharmaceutical plant. This strategic move is set to bolster the company’s position in the radiation therapy sector.
Addressing Manufacturing Challenges in Radiation Therapy
The main bottlenecks faced by radiation therapy research and development include manufacturing capability, production capacity, and logistics. To address these challenges, Full-Life is committed to constructing an advanced production facility that will meet the stringent GMP standards on a 17,000 square meter plot. This new plant will be instrumental in providing the company with internal integrated production solutions and reinforcing its competitive edge in the market.
Philippe van Put’s Outlook on Full-Life’s Competitive Advantages
According to Philippe van Put, Full-Life’s Europe general manager, the establishment of this GMP-compliant facility will offer Full-Life Technologies with strong competitive advantages. By having a facility that adheres to GMP standards, Full-Life is poised to enhance its production capabilities and expand its impact on the radiation therapy landscape.-Fineline Info & Tech
